LNTH Lantheus Holdings Inc

Lantheus Holdings to Host Third Quarter 2016 Earnings Conference Call on November 1, 2016 at 4:30 p.m. Eastern Time

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), today announced that it will host a conference call at 4:30 p.m. ET on Tuesday, November 1, 2016, to discuss its financial and operating results for the third quarter of 2016.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 1805132. A live audio webcast of the call also will be available in the Investors section of the Company’s website at www.lantheus.com.

A replay of the telephone conference call and audio webcast will be available from approximately 8:30 p.m. ET on November 1, 2016 through midnight on November 15, 2016. To access a replay of the conference call, dial 1-855-859-2056 (U.S. callers) or 1-404-537-3406 (international callers), and provide passcode 1805132.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

EN
18/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference...

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 26, 2026, to discuss its financial and operating results for the fourth quarter and full year of 2025. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the sche...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologie...

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced it has completed the previously announced sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. (collectively, “SHINE”). Under the terms of the agreem...

 PRESS RELEASE

Lantheus to Present Florbetaben F 18 Data at CTAD 2025

Lantheus to Present Florbetaben F 18 Data at CTAD 2025 BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new florbetaben F18 data at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, taking place December 1-4, in San Diego, CA. Presentation details are as follows: Poster Presentation Date & Time: Wednesday, December 3, 2025; 7:15...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch